Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits
This article was originally published in The Gray Sheet
Veridex is rolling out Immunicon's circulating tumor cell selection and enumeration IVD systems to roughly 20 U.S. comprehensive cancer centers and clinical labs
You may also be interested in...
Counting circulating tumor cells with J&J/Veridex's cancer diagnostic system before treatment can independently predict progression-free survival and overall survival rates in patients with metastatic breast cancer, according to a 177-patient trial led by Massimo Cristofanilli, MD, University of Texas, published in the Aug. 19 NEJM. The CellSearch system was 510(k) cleared in June and likely will be commercially available this fall, according to Veridex...
Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.